首页> 外文期刊>RSC Advances >Biomimetic enzyme barrier for preventing intestine-derived LPS induced diseases
【24h】

Biomimetic enzyme barrier for preventing intestine-derived LPS induced diseases

机译:防止肠衍生的LPS诱导疾病的仿生酶屏障

获取原文
           

摘要

Biomimetic enzyme barrier (BEB) encapsulated microcapsules with alginate shells were in situ fabricated with a microfluidic electrospray approach for preventing intestine-derived LPS induced diseases. As the alginate shells could protect the contents in gastric juice and release them in the intestine, the inner BEB could form a consecutive immune barrier on the surface of the intestine during the release. Through combining BEB with alkaline phosphatase, the immune barrier could degrade and prevent the permeation of lipopolysaccharide, which enhanced the intestinal barrier function. Thus, the BEB microcapsules were imparted with outstanding ability in preventing intestine-derived LPS induced diseases. Based on an in vivo study, we demonstrated that this BEB microcapsule could effectively protect organ function, restore intestinal barrier integrity, prevent the permeation of LPS and alleviate inflammation. Therefore, the generated microcapsules have potential for clinical applications.
机译:具有藻酸盐壳的仿生酶屏障(BEB)包封的微胶囊原位用微流体电喷雾方法制造,用于预防肠衍生的LPS诱导疾病。由于海藻酸壳可以保护胃液中的内容物并在肠中释放它们,因此内部BEB可以在释放期间在肠道表面形成连续的免疫屏障。通过将BEB与碱性磷酸酶组合,免疫屏障可能降解并防止脂多糖的渗透,这增强了肠道阻隔功能。因此,赋予BEB微胶囊以突出的能力赋予预防肠衍生的LPS诱导疾病。基于在体内研究的基础上,我们证明这种BEB微胶囊可以有效保护器官功能,恢复肠道阻隔完整性,防止LPS渗透和缓解炎症。因此,产生的微胶囊具有临床应用的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号